Albireo Pharma, Inc. Announces Executive Changes
December 09, 2021 at 09:00 am EST
Albireo Pharma, Inc. announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year 2021 after almost three and a half years with the company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of the company, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.